Drug
Elinzanetant clinical trials
Also written NT-814 and GSK1144814.
- studies test it
- 23
- open now
- 1
- in phase 3
- 4
- first study started
- 2008
Keep track of what changes. Save the elinzanetant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
23 studies that test it; most in 2021 (8)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 17
- Phase 2
- 4
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 1
Bayer (19) · GlaxoSmithKline (3) · New York State Psychiatric Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses elinzanetant is read from its arms, and is right about nine times in ten.
Testing it · 23
- Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study ParticipantsRecruitingPhase 1BayerNCT07762287Written as Elinzanetant (BAY 3427080) treatment A
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerActive, not recruitingPhase 3BayerNCT05587296Written as Elinzanetant (BAY3427080)
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the MenopauseCompletedPhase 3BayerNCT05042362Written as Elinzanetant (BAY3427080)
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)CompletedPhase 3BayerNCT05099159Written as Elinzanetant (BAY3427080)
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the MenopauseCompletedPhase 3BayerNCT05030584Written as Elinzanetant (BAY3427080)
- A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With MenopauseCompletedPhase 2BayerNCT06112756Written as Elinzanetant
- A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work NormallyCompletedPhase 1BayerNCT05071729Written as Elinzanetant (BAY3427080)
- Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor SymptomsCompletedPhase 1/2BayerNCT02865538Written as BAY3427080
- A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy WomenCompletedPhase 1BayerNCT06219902Written as Elinzanetant (BAY3427080)
- Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the BodyCompletedPhase 1BayerNCT04845841Written as Elinzanetant (BAY3427080) treatment A
- A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy ParticipantsCompletedPhase 1BayerNCT04889287Written as Elinzanetant (BAY3427080)
- A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy ParticipantsCompletedPhase 1BayerNCT05481528Written as Elinzanetant (BAY3427080)
- A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor SymptomsCompletedPhase 2BayerNCT03596762Written as Elinzanetant (BAY3427080)
- A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female ParticipantsCompletedPhase 1BayerNCT05471817Written as Elinzanetant (BAY3427080)
- A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 YearsCompletedPhase 1BayerNCT05381142Written as Elinzanetant (BAY3427080)
- A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male ParticipantsCompletedPhase 1BayerNCT05351892Written as Elinzanetant (BAY3427080)
- A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female AdultsCompletedPhase 1BayerNCT04981431Written as Elinzanetant (BAY3427080)
- A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female ParticipantsCompletedPhase 1BayerNCT04903821Written as BAY3427080
- Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male SubjectsCompletedPhase 1BayerNCT04654897Written as [14C]-NT-814
- NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical StudyWithdrawnPhase 1/2New York State Psychiatric InstituteNCT02692157Written as NT-814 50 mg
See all 23 studies that test elinzanetant →
Given in every arm · 2 — elinzanetant is usual care beside what is tested
- A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy AdultsCompletedPhase 1BayerNCT05061563Written as Elinzanetant (BAY3427080)
- A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.CompletedPhase 1BayerNCT05028608Written as Elinzanetant (BAY3427080)
Codes
What other systems call elinzanetant · ClinicalTrials.gg INT002177
- MeSH (NLM) C000731952elinzanetantOne source NLM
- UNII (FDA) NZW2BOW35NELINZANETANTConfirmed FDA, NLM, Wikidata
- Wikidata Q108453435elinzanetantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174774ElinzanetantOne source FDA
- DrugBank DB18968One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731952 | elinzanetant | One source NLM |
| UNII (FDA) | NZW2BOW35N | ELINZANETANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q108453435 | elinzanetant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174774 | Elinzanetant | One source FDA |
| DrugBank | DB18968 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.